Baishali M Ambegaonkar

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Mixed dyslipidemias in primary care patients in France
    Laurent Laforest
    Lyon University, Lyon, France
    Vasc Health Risk Manag 8:247-54. 2012
  2. doi request reprint Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada
    Baishali M Ambegaonkar
    Merck and Co Inc, Whitehouse Station, NJ, USA Electronic address
    Eur J Intern Med 24:656-63. 2013
  3. doi request reprint Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong
    Baishali Ambegaonkar
    Global Outcomes Research, Merck and Co, Inc, One Merck Drive, P O Box 100, WS 2E 65, Whitehouse Station, NJ 08889, USA
    Adv Ther 29:427-41. 2012
  4. pmc Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)
    Billie Pettersson
    Center for Medical Technology Assessment, Linkoping University, Linkoping, Sweden
    BMC Public Health 10:737. 2010
  5. doi request reprint Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview
    Sachin Kamal-Bahl
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Clin Ther 31:130-40. 2009
  6. doi request reprint Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database
    Baishali M Ambegaonkar
    Global Health Outcomes, Merck and Co, Inc, Whitehouse Station, NJ 08889 0100, USA
    Metabolism 60:1038-44. 2011
  7. doi request reprint Frequency of diagnosis and treatment of allergic rhinitis among adults with asthma in Germany, France, and the UK: National Health and Wellness Survey
    Vasilisa Sazonov
    Global Outcomes Research, Merck and Co, Inc, Whitehouse Station, NJ 08889 0100, USA
    Curr Med Res Opin 25:1721-6. 2009

Detail Information

Publications7

  1. pmc Mixed dyslipidemias in primary care patients in France
    Laurent Laforest
    Lyon University, Lyon, France
    Vasc Health Risk Manag 8:247-54. 2012
    ..To determine the prevalence of single and mixed dyslipidemias among patients treated with statins in clinical practice in France...
  2. doi request reprint Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada
    Baishali M Ambegaonkar
    Merck and Co Inc, Whitehouse Station, NJ, USA Electronic address
    Eur J Intern Med 24:656-63. 2013
    ..This study evaluated attainment of goal/normal lipid levels in current clinical practice among high-risk patients following lipid-modifying therapy (LMT)...
  3. doi request reprint Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong
    Baishali Ambegaonkar
    Global Outcomes Research, Merck and Co, Inc, One Merck Drive, P O Box 100, WS 2E 65, Whitehouse Station, NJ 08889, USA
    Adv Ther 29:427-41. 2012
    ..The objective of this study was to evaluate attainment of lipid goals and normal levels following lipid-modifying therapy (LMT) and its predictors in a representative sample of Chinese patients from Hong Kong...
  4. pmc Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)
    Billie Pettersson
    Center for Medical Technology Assessment, Linkoping University, Linkoping, Sweden
    BMC Public Health 10:737. 2010
    ..The objective of this study is to estimate the prevalence of dyslipidemia and attainment of goal/normal lipid levels in patients treated with lipid modifying therapy (LMT)...
  5. doi request reprint Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview
    Sachin Kamal-Bahl
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Clin Ther 31:130-40. 2009
    ..Niacin is highly effective at raising high-density lipoprotein cholesterol but remains underused because of the adverse event of flushing...
  6. doi request reprint Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database
    Baishali M Ambegaonkar
    Global Health Outcomes, Merck and Co, Inc, Whitehouse Station, NJ 08889 0100, USA
    Metabolism 60:1038-44. 2011
    ..92). Treatment with ERN (vs other types of LMT) did not significantly increase AHA use, implying that T2DM status did not worsen in this cohort...
  7. doi request reprint Frequency of diagnosis and treatment of allergic rhinitis among adults with asthma in Germany, France, and the UK: National Health and Wellness Survey
    Vasilisa Sazonov
    Global Outcomes Research, Merck and Co, Inc, Whitehouse Station, NJ 08889 0100, USA
    Curr Med Res Opin 25:1721-6. 2009
    ..Concomitant allergic rhinitis (AR) adds to the symptomatic burden of asthma...